G Estevez L, Fortes J L, Adrover E, Peiró G, Margel M, Castellá E, Cuevas J M, Bernet L, Segui M A, Andreu X
Fundación Jiménez Díaz Madrid, Spain.
Clin Transl Oncol. 2009 Jan;11(1):54-9. doi: 10.1007/s12094-009-0311-4.
To evaluate the sequential administration of doxorubicin (A) and cyclophosphamide (C) followed by weekly docetaxel in women with stage II to IIIA breast cancer.
Patients received 60 mg/m(2) of A and 600 mg/m(2) of C every three weeks for four cycles followed by 12 infusions of weekly docetaxel at a dose of 36 mg/m(2) and with a 2-week resting period.
Sixty-three women were included. On an intention-to- treat basis, clinical response rate was 90% (95% CI: 83-98), with 46% complete responses. Breast-conserving surgery could be performed in 43 patients (68%). Complete pathological responses in the breast were confirmed in 17% of patients. No correlations between levels of expression of topoisomerase II alpha, survivin or p27 and the pathological response were detected. The study treatment was generally well tolerated.
Neoadjuvant AC followed by weekly docetaxel is a feasible regimen for patients with early-stage breast cancer.
评估多柔比星（A）和环磷酰胺（C）序贯给药，随后每周给予多西他赛用于治疗II至IIIA期乳腺癌女性患者的疗效。
患者每三周接受60mg/m²的A和600mg/m²的C，共四个周期，随后每周给予12次多西他赛静脉输注，剂量为36mg/m²，每两个周期休息2周。
纳入63名女性患者。在意向性分析的基础上，临床缓解率为90%（95%CI：83-98），其中46%为完全缓解。43名患者（68%）可行保乳手术。17%的患者乳腺获得完全病理缓解。未检测到拓扑异构酶IIα、生存素或p27的表达水平与病理缓解之间存在相关性。研究治疗总体耐受性良好。
新辅助AC序贯每周多西他赛治疗方案对于早期乳腺癌患者是可行的。
